Solve Therapeutics

Q: What industry does Solve Therapeutics belong to?

Solve Therapeutics is in the industry of: Manufacturing , Pharmaceuticals , Business Services

Manufacturing · California, United States · 11-50 Employees

View Company Info for Free

Overview

Headquarters

1025 Alameda de las Pulgas PMB 122, Belm...

Phone Number

(858) 357-4137

Website

www.solvetx.com

Revenue

$7.4 Million

Industry

Manufacturing

Pharmaceuticals

Business Services

Research & Development

ZI Rank: 1

Signal Type

Feb

Mar

Apr

May

Jun

Jul

ZI Rank

About Solve Therapeutics

Solve Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of next-generation ADCs and a novel diagnostic platform for solid tumors. With its proprietary CloakLink hydrophilic linker system and a focus on selectively expressed tumor antigens, Solve is engineering therapeutics designed to safely and effectively offer benefit to patients with life-threatening cancers. Its diagnostic approach offers the potential of precise, noninvasive patient selection.Explore more

Is this data correct?

View contact profiles from Solve Therapeutics

Popular SearchesSolve Therapeutics IncSIC Code 28,283NAICS Code 32,325Show more

Solve Therapeutics Org Chart

David Johnson

Chief Executive Officer & Founder

Phone

Brian Lannutti

Executive VP, Research & Development

Phone

Get the full picture

Jeff Watkins

Senior VP, Antibody Technologies

Phone

Get the full picture

Is Solve Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Click to see if Solve Therapeutics had a recent Job posting/layoffs

Earning: See what the market has to say on Solve Therapeutics recently announced quarterly report

Competitive Alert! Recent activity has been detected by your competitor Masked Content

Website visits: Recent activity has been detected on your website

Funding: Get notified immidiatlly once Solve Therapeutics has new funding data

Check if Solve Therapeutics has recently received funding, and reach out quickly before it becomes old news!

Product Launch: Get notified when Solve Therapeutics launches new products

Check out if Solve Therapeutics is spiking on competitors!

Solve Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic

Congratulate Masked Content for being promoted to Masked Content at Solve Therapeutics

Recommended Actions

Find VP level buyers at Solve Therapeutics

Find 2 more new buyers

View Email Formats for Solve Therapeutics

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

Solve Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

Solve Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Solve Therapeutics.

Solve Therapeutics financials insights

Gather financial insights about Solve Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2025

Other Financing Round

$120M

See All Solve Therapeutics's Financials Insights

Solve Therapeutics Tech Stack

A closer look at the technologies used by Solve Therapeutics

Lua

See more technologies

Most Recent Scoops

Project

Solve Therapeutics is sponsoring an interventional clinical trial focused on SLR-108 PET imaging in metastatic solid tumors. The trial began in July 2026 with the expected completion date of February 2028. The trial is currently recruiting participants.

Laboratory Operations, Medical Research, Clinical Operations

Project

Solve Therapeutics is sponsoring an interventional clinical trial focused on SLV-154 treatment of metastatic solid tumors. The trial began in May 2025 with the expected completion date of April 2027. The trial is currently recruiting participants.

Laboratory Operations, Medical Research, Clinical Operations

Project

Solve Therapeutics is sponsoring an interventional clinical trial focused on SLV-324 treatment of metastatic solid tumors. The trial began on August 2025 with the expected completion date of August 2027. The trial is currently in phase one.

Laboratory Operations, Medical Research, Clinical Operations

Funding

See more scoops

Top Manufacturing Companies

Frequently Asked Questions Regarding Solve Therapeutics

What is Solve Therapeutics's official website?

Solve Therapeutics's official website is www.solvetx.com

What is Solve Therapeutics's Revenue?

Solve Therapeutics's revenue is $7.4 Million

What is Solve Therapeutics's SIC code?

Solve Therapeutics's SIC: 28,283

What is Solve Therapeutics's NAICS code?

Solve Therapeutics's NAICS: 32,325

How many employees does Solve Therapeutics have?

Solve Therapeutics has 11-50 employees

What industry does Solve Therapeutics belong to?

Solve Therapeutics is in the industry of: Manufacturing, Pharmaceuticals, Business Services

What technology does Solve Therapeutics use?

Some of the popular technologies that Solve Therapeutics uses are: GoCentral, Google AdSense, OpenResty, Lua

How do I contact Solve Therapeutics?

Solve Therapeutics contact info: Phone number: (858) 357-4137 Website: www.solvetx.com

What does Solve Therapeutics do?

What are Solve Therapeutics social media links?

Solve Therapeutics Linkedin page

Who invested in Solve Therapeutics?

Solve Therapeutics has 4 investors including B Capital Group, Yosemite, Ally Bridge Group and Abingworth.

Is Solve Therapeutics a public company?

Solve Therapeutics is private company therefore does not currently have an official ticker symbol

See more information about Solve Therapeutics

Sell Smarter. Win Faster.

Level up your game to ZoomInfo Copilot, intuitive AI that turns your data and high-quality ZoomInfo data into an unfair advantage for your go-to-market teams.